Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 12-85 lat (dla mięsaka Ewinga) lub 18-85 lat (dla innych nowotworów)
- •Nowotwór można zmierzyć na obrazach medycznych
- •Wystarczająca funkcja wątroby, nerek i krwiotwórczych
- •Dobry stan ogólny - pacjent może prowadzić normalne czynności
- •Spodziewana długość życia co najmniej 12 tygodni
- •Dostęp do próbki nowotworu do badania (archiwalna lub świeża)
✗ Disqualifies
- •Poprzeczne leczenie podobnymi lekami działającymi na receptor DR5
- •Chemioterapia lub inne leki przeciwnowotworowe w ciągu ostatnich 4 tygodni
- •Alergia na INBRX-109 lub podobne białka
- •Radioterapia wątroby w ciągu ostatnich 12 miesięcy
- •Przeszczepianie szpiku костного w ciągu ostatnich 5 lat
- •Inne nowotwory równocześnie lub w przeszłości
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 85 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (37)
HonorHealth Research Institute
Scottsdale, United States
Precision NextGen Oncology and Research
Beverly Hills, United States
City of Hope
Duarte, United States
Valkyrie Clinical Trials
Los Angeles, United States
Children's Hospital of Orange County-Rady Children's Health
Orange, United States
University of California, San Diego (UCSD) - Moores Cancer Center
San Diego, United States
University of California, San Francisco (UCSF)
San Francisco, United States
Sarcoma Oncology Center
Santa Monica, United States
University of Colorado Hospital
Aurora, United States
Emory University - Winship Cancer Institute
Atlanta, United States
The University of Chicago
Chicago, United States
University of Michigan
Ann Arbor, United States
START Midwest Michigan, PC
Grand Rapids, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
Oregon Health & Science University
Portland, United States
Children's Hospital of Philadelphia- Center for Childhood Cancer Research
Philadelphia, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, United States
Vanderbilt University School of Medicine
Nashville, United States
UT MD Anderson Cancer Center
Houston, United States
NEXT Oncology
San Antonio, United States
University of Virginia
Charlottesville, United States
NEXT Oncology - Virginia
Fairfax, United States
Centre Leon Berard
Lyon, France
Gustave Roussy
Villejuif, France
La Fondazione e l'Istituto di Candiolo
Candiolo, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
University Medical Center Groningen
Groningen, Netherlands
Academisch Ziekenhuis Leiden
Leiden, Netherlands
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Spain
Great North Children's Hospital
London, United Kingdom
University College London Hospital
London, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Trial contact
Study Director, -Inhibrx
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.